OptimizeRx Corp (OPRX) beat Q3 2026 estimates with 29% adjusted EBITDA margins and advancing DSP integrations, but a 17% revenue drop and reduced full-year outlook weigh on the near-term picture.
If you had read both the bullish and bearish August 2025 takes on OptimizeRx and decided to sit it out, the past year probably felt like a bullet dodged. For OptimizeRx shareholders, the loss over the past year was 51.6%, including dividends. That move now sits alongside weaker 2026 results and new product headlines. However, the real question is simpler: What early assumptions about digital health growth and data privacy risk were already on record before any of that unfolded? Narratives are...
Trade Desk (NasdaqGM:TTD) is linking with OptimizeRx to pipe point of care EHR media into its platform via OpenPath. The integration gives life sciences advertisers programmatic access to OptimizeRx's proprietary healthcare professional inventory inside The Trade Desk's system. The move expands healthcare focused media options for brands that want premium placements in clinical settings where prescribing decisions are made. The OptimizeRx OpenPath link into The Trade Desk sits against...
OptimizeRx (OPRX) has an average rating of buy and mean price target of $12.40, according to analyst
The move gives life sciences advertisers a more streamlined way to bring specialized healthcare audiences into their broader digital media strategies.
Experienced pharmaceutical and healthcare executive joins advisory board to help accelerate innovation and strengthen life sciences marketing technologyWALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced the appointment of Troy Sarich as a Company advisor. Sarich
This is the newest page. Registered accounts read further back.